Needham Sees Buying Opportunity in This Penny Stock

GERN stock has more than doubled off its December lows

Karee Venema

Apr 9, 2019 at 10:08 AM

GERN

Geron Corporation (NASDAQ:GERN) stock is red-hot today, after Needham upgraded the cancer specialist to "buy" from "hold, and assigned a $3 price target -- a 63% premium to last night's close. The brokerage firm said the "negative optics of a big pharma passing on imetelstat" creates a buying opportunity for the penny stock. This comes after Johnson & Johnson (JNJ) subsidiary Janssen terminated its imetelstat collaboration with Geron last September.

In reaction, GERN stock is up 3.2% at $1.90, pacing toward its sixth straight win. Since bottoming below the $1 level in late December, the shares have more than doubled, but have struggled against the $2 mark -- near a massive Sept. 27 bear gap.

Analysts are optimistic, with all three in coverage maintaining a "buy" or better rating on GERN. Plus, the average 12-month price target sits all the way up at $3.63.

Short sellers, on the other hand, have heavily targeted GERN. The 41.09 million shares currently sold short represents 22% of the stock's available float, or 10.1 times the average daily pace of trading.

Follow @Schaeffers

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.